



**EFFECTS OF AUTOPHAGY INHIBITION ON NEWCASTLE DISEASE  
VIRUS-INDUCED ONCOLYSIS IN BREAST CANCER CELLS**

**By**

**MEGAT MOHAMAD IRFAN BIN ROZILAH**

**Thesis Submitted to the School of Graduate Studies, Universiti Putra  
Malaysia, in Fulfilment of the Requirements for the Degree of Master of  
Science**

**July 2022**

**FBSB 2022 17**

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in  
fulfilment of the requirement for the degree of Master of Science

**EFFECTS OF AUTOPHAGY INHIBITION ON NEWCASTLE DISEASE  
VIRUS-INDUCED ONCOLYSIS IN BREAST CANCER CELLS**

By

**MEGAT MOHAMAD IRFAN BIN ROZILAH**

**July 2022**

**Chair : Saila Ismail, PhD**  
**Faculty : Biotechnology and Biomolecular Sciences**

Researchers have been developing oncolytic viruses (OVs) as an alternative treatment to treat advanced cancer and to combat against the cancer cell resistance towards chemotherapy and radiotherapy. Newcastle disease virus (NDV) is an avian virus which selectively replicates in mammalian cancer cells due to the lack of antiviral immune response in these cells, thus making NDV a good candidate for oncolytic virotherapy. Recently, scientists have explored a novel strategy to fight cancer that is by inhibiting autophagy. Autophagy is a highly conserved cellular degradation mechanism which recycles unused cytoplasmic constituent into new nutrients. Importantly, studies have demonstrated that inhibition of autophagy enhanced NDV-induced oncolysis in several human cancer cells including gastric carcinoma, lung, and glioma cancer cells. Even though studies have been done to show NDV oncolytic effect in breast cancer cells, the effect of autophagy inhibition on NDV-induced oncolysis in breast cancer cells remains unknown. The main aim of this study was to examine the effect of autophagy inhibition on NDV-induced oncolysis in human breast cancer cells MCF7. Two approaches were utilised to inhibit autophagy which were pharmacological inhibitors and short-interfering RNA (siRNA)-mediated protein knockdown. Briefly, MCF7 cells were infected with the recombinant NDV strain AF2240 with GFP (rAF-GFP) with or without autophagy inhibition by the pharmacological autophagy inhibitors, SAR405 and chloroquine (CQ); or by siRNA-mediated knockdown of the autophagy protein Beclin-1 (BECN1). Autophagic activity was observed and quantified using fluorescence microscopy and fluorometer, respectively. MTT assay was used to measure cell death and viral replication was quantified using fluorometer. The results showed that NDV induced autophagy in MCF7 cells at 2 hours post-infection (hpi). Importantly, both autophagy inhibitors, SAR405 and CQ, had no significant effect on NDV-induced oncolysis in MCF7 breast cancer cells, as measured at 24, 48 and 72 hpi. Furthermore, in contrast to our hypothesis, siRNA knockdown of BECN1 significantly reduced the cell death of NDV-infected MCF7 cells at 24 hpi by ~10%, but not at 48 and 72 hpi. Further experiment suggests that this could

be due to the reduction of viral replication by more than 50% following treatment with BECN1-targeting siRNA at 24 hpi. In conclusion, NDV induces autophagy in breast cancer cells. Importantly, inhibition of autophagy does not enhance the oncolytic efficacy of NDV in breast cancer cells, instead it reduces the cell death, possibly by suppressing viral replication. Further work can be done to determine if induction of autophagy can enhance the oncolytic efficacy of NDV in breast cancer cells.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia  
sebagai memenuhi keperluan untuk ijazah Master Sains

**KESAN RENCATAN AUTOFAGI TERHADAP ONKOLISIS YANG DIARUH  
OLEH VIRUS PENYAKIT SAMPAR AYAM DALAM SEL BARAH  
PAYUDARA**

Oleh

**MEGAT MOHAMAD IRFAN BIN ROZILAH**

**Julai 2022**

**Pengerusi : Saila Ismail, PhD**  
**Fakulti : Bioteknologi dan Sains Biomolekul**

Penyelidik telah mula membangunkan virus onkolitik sebagai rawatan alternatif untuk merawat kanser peringkat akhir dan juga rawatan untuk sel barah yang rintang terhadap kemoterapi dan radioterapi. Virus penyakit sampar ayam (NDV) adalah sejenis virus yang menjangkiti burung dan telah menjadi calon untuk viroterapi onkolitik kerana telah menunjukkan kebolehan untuk mereplikasi di dalam sel barah mamalia secara selektif kerana kekurangan tindak balas imun antivirus. Saintis telah meneroka strategi baru untuk melawan kanser dengan cara perencatan autofagi. Autofagi ialah mekanisme degradasi selular yang mengitar semula jujuk sitoplasma yang tidak digunakan kepada nutrien baharu. Kajian telah menunjukkan perencatan autofagi meningkatkan kesan onkolisis yang disebabkan oleh NDV di dalam beberapa sel kanser manusia termasuklah sel-sel barah karsinoma gastrik, peparu dan juga glioma. Walaupun kajian telah menunjukkan NDV mempunyai kesan onkolisis ke atas sel barah payudara, kesan rancangan autofagi terhadap kesan onkolisis oleh NDV ke atas sel barah payudara masih belum diketahui. Matlamat utama kajian ini adalah untuk mengkaji kesan rancangan autofagi terhadap kesan onkolisis yang disebabkan oleh NDV di dalam sel barah payudara MCF7. Dua jenis pendekatan telah digunakan iaitu perencat farmakologi dan penyahfungsian siRNA protein autofagi Beclin-1. Secara ringkas, sel MCF7 telah dijangkiti dengan NDV rekombinan strain AF2240 dengan GFP (rAF-GFP) bersama atau tanpa perencat farmakologi autofagi, SAR405 dan chloroquine (CQ); atau dengan penyahfungsian siRNA protein autofagi Beclin-1 (BECN1). Aktiviti autofagi telah dicerap dan diukur menggunakan mikroskop pendarflour dan fluorometer. Ujian MTT telah digunakan untuk mengukur kematian sel dan replikasi virus diukur menggunakan fluorometer. Keputusan menunjukkan NDV telah mengaruh autofagi di dalam sel MCF7 pada 2 jam selepas jangkitan (hpi). Kedua-dua perencat autofagi, SAR405 dan CQ tidak mempunyai kesan onkolisis oleh NDV yang ketara ke atas sel barah payudara seperti yang diukur pada 24, 48 dan 72 hpi. Walau bagaimanapun, penyahfungsian siRNA protein autofagi BECN1 telah

mengurangkan kematian sel MCF7 secara ketara sebanyak ~10% pada 24 hpi, tetapi tidak pada 48 dan 72 hpi. Eksperimen lanjutan mencadangkan hal ini mungkin disebabkan oleh pengurangan replikasi virus melebihi 50% selepas penyahfungsian siRNA pada 24 hpi. Kesimpulannya, NDV mengaruh autofagi di dalam sel barah payudara. Rencatan autofagi tidak meningkatkan kesan onkolisis oleh NDV ke atas sel barah payudara, sebaliknya mengurangkan kematian sel-sel kemungkinan dengan menyekat replikasi virus. Kajian lanjut boleh dijalankan untuk menentukan sama ada aruhan autofagi boleh meningkatkan keberkesanan onkolisis oleh NDV ke atas sel barah payudara.



## ACKNOWLEDGEMENTS

Firstly, I would like to thank Allah for the strength to complete this long and difficult journey. Next, I would like to express my sincere gratitude and many thanks to my supervisor, Dr. Saila Ismail for her expert guidance, patience, passion, and support throughout the journey of completing the project.

I also would like to thank my supervisory committee, Prof. Datin Paduka Dr. Khatijah Mohd Yusoff and Assoc. Prof. Dr. Eddie Chia Suet Lin for their help, expertise, knowledge, guidance, and encouragement throughout the project.

Many thanks to my fellow lab mates in Virology 1 and Virology 2 for the help, friendship, and memories.

Lastly, I dedicated this thesis to my mother, Raja Norazlin binti Raja Shahardin and would like to thank her for her unconditional love, support, and motivation throughout my life. I love you so much!

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

**Saila Ismail, PhD**

Senior Lecturer  
Faculty of Biotechnology and Biomolecular Sciences  
Universiti Putra Malaysia  
(Chairman)

**Khatijah Mohd Yusoff, PhD**

Professor, Datin Paduka  
Faculty of Biotechnology and Biomolecular Sciences  
Universiti Putra Malaysia  
(Member)

**Chia Suet Lin, PhD**

Associate Professor  
Faculty of Biotechnology and Biomolecular Sciences  
Universiti Putra Malaysia  
(Member)

---

**ZALILAH BINTI MOHD SHARIFF, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date: 14 December 2023



## TABLE OF CONTENTS

<b>ABSTRACT</b>	<b>Page</b>
<b>ABSTRAK</b>	i
<b>ACKNOWLEDGEMENTS</b>	iii
<b>APPROVAL</b>	v
<b>DECLARATION</b>	vi
<b>LIST OF TABLES</b>	viii
<b>LIST OF FIGURES</b>	xiii
<b>LIST OF ABBREVIATIONS</b>	xiv
	xvi

### CHAPTER

<b>1</b>	<b>INTRODUCTION</b>	<b>1</b>
	1.1 Background	1
	1.2 Objectives	2
<b>2</b>	<b>LITERATURE REVIEW</b>	<b>3</b>
	2.1 Cancer	3
	2.1.1 Breast cancer	3
	2.1.2 Current treatments for cancer	3
	2.2 New castle disease virus	4
	2.2.1 NDV as an oncolytic virus	5
	2.2.2 NDV strain AF2240	6
	2.3 Autophagy	6
	2.3.1 Phosphoinositide 3-kinase (PI3K) and Autophagy-related (Atg) genes	7
	2.3.2 Role of autophagy in cancer	10
	2.3.3 Role of autophagy in viral replications	12
	2.3.4 Autophagy modulates oncolytic activity of NDV in cancer cells	12
<b>3</b>	<b>MATERIALS AND METHODS / METHODOLOGY</b>	<b>15</b>
	3.1 Cell culture	15
	3.1.1 Preparation of media	15
	3.1.2 Maintenance of human breast cancer MCF7 cell line	15
	3.1.3 Maintenance of human non-cancerous lung fibroblast MRC5 and human colon adenocarcinoma SW620 cell lines	16
	3.1.4 Mycoplasma testing	16
	3.2 Propagation of Newcastle disease virus	16
	3.2.1 Hemagglutination assay (HA)	17
	3.2.2 NDV rAF-GFP culturing in embryonated chicken eggs	17
	3.2.3 Purification of NDV rAF-GFP from the allantoic fluid	17
	3.2.4 Quantification of NDV rAF-GFP titre by plaque assay	18
	3.3 NDV rAF-GFP infection in cell lines	18

3.4	Treatment of MCF7 cell line with pharmacological autophagy inhibitors	19
3.5	Transient gene knockdown using short interfering RNA (siRNA) in MCF7 cell line	19
3.6	Western blot analysis	20
3.6.1	Preparation of sample for western blot analysis	20
3.6.2	Sodium dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE)	21
3.6.3	Protein transfer	21
3.6.4	Staining of transferred proteins with antibodies	21
3.6.5	Visualisation by colorimetric alkaline-phosphatase assay	22
3.7	Measurement of cell death by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay	22
3.8	Quantification of fluorescent-labelled proteins by fluorometer	23
3.8.1	Measurement of autophagy induction	23
3.8.2	Measurement of viral replication	23
3.9	Fluorescence and phase contrast microscopy	24
3.10	Statistical analysis	24
<b>4</b>	<b>RESULTS</b>	<b>25</b>
4.1	Mycoplasma contamination test	25
4.2	Propagation of NDV rAF-GFP	26
4.2.1	Propagation of virus in embryonic chicken eggs	26
4.2.2	Quantification of viral titre	28
4.2.3	Confirmation of genetic stability of the newly propagated virus	29
4.3	Determination of the optimal multiplicity of infection (MOI) of NDV rAF-GFP for subsequent infection experiments	29
4.4	Induction of autophagy by NDV in MCF7 cells	32
4.5	Effect of autophagy inhibition by pharmacological inhibitors on NDV-induced oncolysis in MCF7 cells	33
4.5.1	Determination of the optimal concentrations of SAR405 and CQ to inhibit autophagy in MCF7 cells	33
4.5.2	Effect of autophagy inhibition by SAR405 and CQ on NDV-induced oncolysis in MCF7 cells	35
4.5.3	Confirmation that both SAR405 and CQ at the optimal concentrations do inhibit NDV-induced autophagy in MCF7 cells	40
4.6	Effect of autophagy inhibition by short-interfering RNA (siRNA)-mediated knockdown	41

	of an autophagy protein on NDV-induced oncolysis in MCF7 cells	
	4.6.1 Optimisation of siRNA-mediated knockdown of the autophagy protein BECN1 in MCF7 cells	41
	4.6.2 Confirmation that siRNA-mediated knockdown of BECN1 does inhibit NDV-induced autophagy in MCF7 cells	43
	4.6.3 Effect of autophagy inhibition by siRNA-mediated knockdown of BECN1 on NDV-induced oncolysis in MCF7 cells	44
	4.7 Effect of autophagy inhibition on NDV replication in MCF7 cells	47
<b>5</b>	<b>DISCUSSION</b>	<b>50</b>
	5.1 NDV infection induces autophagy in breast cancer cells	50
	5.2 Inhibition of autophagy does not affect NDV-induced oncolysis in breast cancer cells	50
	5.3 Autophagy pathway mediates NDV replication in breast cancer cells	53
<b>6</b>	<b>CONCLUSION AND RECOMMENDATIONS FOR FUTURE RESEARCH</b>	<b>55</b>
	<b>REFERENCES</b>	<b>56</b>
	<b>APPENDICES</b>	<b>68</b>
	<b>BIODATA OF STUDENT</b>	<b>70</b>
	<b>LIST OF PUBLICATIONS</b>	<b>71</b>

## LIST OF TABLES

<b>Table</b>		<b>Page</b>
2.1	Commonly used pharmacological inhibitors of autophagy	11
2.2	Summary of known interactions between NDV and autophagy in human cancer cells	14
3.1	annealed siRNA duplexes purchased from Bioneer Corporation, Korea	19
3.2	Buffers and reagents for western blot used in this project	20
3.3	Antibodies for western blot used in this project	22

## LIST OF FIGURES

Figure		Page
2.1	Structure and genomic organisation of NDV	5
2.2	Induction of autophagy by NDV	9
4.1	The cultured MCF7, MRC5 and SW620 cells are confirmed not to have mycoplasma contamination	26
4.2	Purification and titration of purified NDV	27
4.3	Titration of NDV rAF-GFP stock by plaque assay using SW620 cells	28
4.4	NDV rAF-GFP-infected cells emit green fluorescence signal	29
4.5	MOI-response of NDV infection in MCF7 cells	30
4.6	MOI-response of NDV infection in MRC5 cells	31
4.7	NDV causes significantly higher cell death in MCF7 compared to MRC5 cells	31
4.8	NDV induces autophagy in MCF7 cells, as observed at 2hpi	33
4.9	Time- and dose-responses of SAR405 in MCF7 cells	34
4.10	Time- and dose-responses of CQ in MCF7 cells	35
4.11	Cell morphology of MCF7 cells after NDV infection and/or treatment with SAR405 at 48hpi	36
4.12	SAR405 does not enhance the cell death in NDV-infected MCF7 cells	37
4.13	Cell morphology of MCF7 cells after NDV infection and/or treatment with CQ at 48hpi	38
4.14	CQ does not enhance the cell death in NDV-infected MCF7 cells	39
4.15	SAR405 and CQ inhibit NDV- and Torin2-induced autophagy in MCF7 cells, as observed at 2h post-treatment	40

4.16	Time- and duplex-responses of siRNA-mediated knockdown of BECN1	42
4.17	Knockdown of BECN1 does not affect the growth of MCF7 cells	43
4.18	SiRNA-mediated knockdown of BECN1 inhibits NDV- and Torin2-induced autophagy in MCF7 cells, as observed at 2h post-treatment	44
4.19	Cell morphology of MCF7 cells after NDV infection and/or Beclin-1 knockdown at 48hpi	45
4.20	Knockdown of BECN1 significantly decreases the cell death in NDV-infected MCF7 cells as compared to Scr-transfected MCF7 cells at 24hpi	46
4.21	Knockdown of BECN1 significantly decreases viral replication in MCF7 cells at 24hpi	48
4.22	Viral replication is significantly increased in MCF7 cells treated with 5 $\mu$ M of CQ at 24hpi	49

## LIST OF ABBREVIATIONS

3-MA	3-Methyladenine
A549	Human lung cancer cell line (ATCC)
A549/DDP	Cisplatin-resistant A549
A549/PTX	Paclitaxel-resistant A549
Ambra 1	Autophagy and Beclin 1 Regulator 1
AP	Alkaline phosphatase
Atg	Autophagy-related
Baf A1	Bafilomycin A1
Bcl-2	B-cell lymphoma 2 gene
BECN1	Beclin 1
Bif-1	Bax interacting factor 1
CO <sub>2</sub>	Carbon dioxide
CQ	Chloroquine
DMEM	Dulbecco's Modified Eagle Medium
DMSO	Dimethyl sulfoxide
DTX	Docetaxel
eIF2 $\alpha$	Eukaryotic translational initiation factor 2 $\alpha$
ER	Endoplasmic reticulum
HA	Hemagglutination assay
HCQ	Hydroxychloroquine
hpi	Hours-post infection
IFN	Interferon
IRE1 $\alpha$	Inositol-requiring transmembrane kinase endoribonuclease-1 $\alpha$
JNK	c-Jun N-terminal kinase

LC3	Light chain 3
MCF7	Human breast cancer cell line (ATCC)
MDA-MD-231	Human breast cancer cell line (ATCC)
MOI	Multiplicity of infection
MRC5	Normal human lung fibroblasts cell line (ATCC)
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium reduction assay
NDV	Newcastle disease virus
NDV rAF-GFP	Recombinant Newcastle disease virus strain AF2240 with green fluorescent protein
OV	Oncolytic virus
PBS	Phosphate buffer saline
PE	Phosphatidylethanolamine
PERK	Protein kinase R-like ER kinase
PI3K	Phosphoinositide 3-kinase
PI3K3C	Class III PI3K complex
PVDF	Poly(vinylidene fluoride)
QC	Quinacrine
rAV	Average of the radius
RFU	Relative fluorescence unit
RPMI 1640	Roswell Park Memorial Institute 1640 Medium
Scr	Scrambled (non-targeting)
SDS-PAGE	Sodium dodecyl-sulphate polyacrylamide gel electrophoresis
SEM	Standard error of the mean
siRNA	Short-interfering RNA
SKVCR	VCR-resistant ovarian carcinoma cells



SQSTM1/p62	Sequestosome 1
SW620	Human colon adenocarcinoma cell line (ATCC)
UPM	Universiti Putra Malaysia
UVRAG	UV radiation resistance-associated gene
VCR	Vincristine
Vps15	Vacuolar protein sorting
XBP-1	X-box binding protein 1
xg	Relative centrifugal force



# CHAPTER 1

## INTRODUCTION

### 1.1 Background

Normal cells proliferate, mature, and die after a period by apoptosis or programmed cell death. Cancer cells, on the other hand, are aged cells that do not die but instead proliferate uncontrollably and lose their functionality. Cancer patients have undergone combination of either chemotherapy, radiotherapy or immunotherapy as surgery alone could not remove the tumour all the time. The emergence of chemo- and radio-resistant cancer cells has encouraged researchers to develop alternative cancer treatments (Russell et al., 2012). Hence, the interest in using and developing oncolytic viruses (OVs) as an alternative cancer treatment has grown in many researchers (Burke et al., 2015).

Newcastle disease virus (NDV) is a virus that can cause diseases to avian species around the world and the oncolytic property of NDV has first been reported by Prince & Ginsberg (1957) in Ehrlich ascites tumour cells. Like the other OVs, NDV has been demonstrated to infect and kill various cancer cells including leukaemia, lymphoma, melanoma, neuroblastoma, colon carcinoma, lung carcinoma, prostate carcinoma, breast carcinoma, gastric carcinoma, mesothelioma, and head and neck carcinoma at a much higher magnitude compared to its effect on normal cells (Zamarin & Palese, 2012). Even though NDV can effectively infect and kill cancer cells, the virus could also develop viral-resistant cancer cells (Chia et al., 2014). However, with the recent advancement of genetic engineering, few recombinant NDVs have been produced to enhance their oncolytic efficacy (Bai et al., 2014; Harper et al., 2021; Mohamed Amin et al., 2019; Najmuddin et al., 2020; Ramamurthy et al., 2021; Vijayakumar et al., 2020; Y. Wu et al., 2012).

Recently, researchers have discovered a novel strategy to fight cancer which is by inhibiting the autophagy pathway (Chude & Amaravadi, 2017). Autophagy is an intracellular degradation pathway which degrades and converts unused cytoplasmic constituents into new nutrients. It can be induced when the cell is starved, exposed to radiation, or infected to promote cell survival. Some studies have shown that in patients undergoing chemotherapy treatment, autophagy can be induced and acts as a pro-survival pathway to help the cancer cells such as colorectal, bladder, gastric, and breast cancer cells, to be chemo resistant (Li et al., 2016; Lin et al., 2017; Yang et al., 2015; Yu et al., 2015).

Several studies have reported that NDV infection can induce autophagy in glioma cells, lung cancer cells, and stomach adenocarcinoma cells (Bu et al., 2015; Hu et al., 2015; Jiang et al., 2014; Meng et al., 2012). Importantly, inhibition of autophagy increased the cancer cell death that was initially caused by NDV in

several lung cancer cell lines (Hu et al., 2015; Jiang et al., 2014; Meng et al., 2014). However, a study found that autophagy inhibition caused a reduction in NDV-induced oncolysis in stomach adenocarcinoma cells (Bu et al., 2015). Autophagy inhibition reduces NDV-induced immunogenic cell death in human melanoma cells (Shao et al., 2019).

Although several strains of NDV including the locally isolated strain AF2240 have been shown to have oncolytic effects on breast cancer cells (Ahmad et al., 2015; Al-Ziaydi et al., 2020; Ghrici et al., 2013; Kalantari et al., 2020; Mohamed Amin et al., 2019; Othman et al., 2010), no study has been done to determine the effect of autophagy inhibition on NDV-induced oncolysis in breast cancer cells. In this current study, it was hypothesised that inhibition of autophagy could enhance NDV-induced oncolysis in breast cancer cells.

## **1.2 Objectives**

The objectives of this study were:

- 1) to determine the ability of NDV to induce autophagy in breast cancer cells;
- 2) to examine the effect of autophagy inhibition on NDV-induced oncolysis in breast cancer cells; and
- 3) to determine the effect of autophagy inhibition on NDV replication in breast cancer cells.

## REFERENCES

- Ahmad, U., Ahmed, I., Keong, Y. Y., Abd Manan, N., & Othman, F. (2015). Inhibitory and apoptosis-inducing effects of newcastle disease virus strain AF2240 on mammary carcinoma cell line. *BioMed Research International*, 2015. <https://doi.org/10.1155/2015/127828>
- Alonso, M. M., Jiang, H., Yokoyama, T., Xu, J., Bekele, N. B., Lang, F. F., Kondo, S., Gomez-Manzano, C., & Fueyo, J. (2008). Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. *Molecular Therapy: The Journal of the American Society of Gene Therapy*, 16(3), 487–493. <https://doi.org/10.1038/SJ.MT.6300400>
- Al-Ziaydi, A. G., Al-Shammari, A. M., Hamzah, M. I., Kadhim, H. S., & Jabir, M. S. (2020). Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death. *VirusDisease*, 31(3), 341–348. <https://doi.org/10.1007/s13337-020-00612-z>
- Andtbacka, R. H. I., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K. A., Amatruda, T., Zager, J. S., Cranmer, L., Hsueh, E., Chen, L., Shilkrut, M., & Kaufman, H. L. (2016). Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. *Annals of Surgical Oncology*, 23(13), 4169–4177. <https://doi.org/10.1245/s10434-016-5286-0>
- Bai, F. L., Yu, Y. H., Tian, H., Ren, G. P., Wang, H., Zhou, B., Han, X. H., Yu, Q. Z., & Li, D. S. (2014). Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. *Cancer Biology & Therapy*, 15(9), 1226–1238. <https://doi.org/10.4161/CBT.29686>
- Bello, M. J., Pestaña, A., Rey, J. A., de Campos, J. M., Kusak, M. E., Vaquero, J., & Sarasay, J. L. (1994). Allelic loss at 1 p is associated with tumor progression of meningiomas. *Genes, Chromosomes and Cancer*, 9(4), 296–298. <https://doi.org/10.1002/gcc.2870090411>
- Botta, G., Passaro, C., Libertini, S., Abagnale, A., Barbato, S., Maione, A. S., Hallden, G., Beguinot, F., Formisano, P., & Portella, G. (2012). Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo. *Human Gene Therapy*, 23(6), 623–634. <https://doi.org/10.1089/HUM.2011.120>
- Bu, X.-F., Wang, M.-B., Zhang, Z.-J., Zhao, Y.-H., Li, M., & Yan, Y.-L. (2015). Autophagy is involved in recombinant Newcastle disease virus (rL-RVG)-induced cell death of stomach adenocarcinoma cells in vitro. *International Journal of Oncology*, 47(2), 679–689. <https://doi.org/10.3892/ijo.2015.3039>
- Burke, J., Nieva, J., Borad, M. J., & Breitbach, C. J. (2015). Oncolytic viruses: perspectives on clinical development. *Current Opinion in Virology*, 13, 55–60. <https://doi.org/10.1016/j.coviro.2015.03.020>

- Centers for Disease Control and Prevention. (2021). What Is Breast Cancer? | CDC. Centers for Disease Control and Prevention. [https://www.cdc.gov/cancer/breast/basic\\_info/what-is-breast-cancer.htm](https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm)
- Cheng, J.-H., Sun, Y.-J., Zhang, F.-Q., Zhang, X.-R., Qiu, X.-S., Yu, L.-P., Wu, Y.-T., & Ding, C. (2016). Newcastle disease virus NP and P proteins induce autophagy via the endoplasmic reticulum stress-related unfolded protein response. *Scientific Reports*, 6(1), 24721. <https://doi.org/10.1038/srep24721>
- Cheow, P.-S., Tan, T. K., Song, A. A.-L., Yusoff, K., & Chia, S. L. (2020). An improved method for the rescue of recombinant Newcastle disease virus. *BioTechniques*, 68(2), 96–100. <https://doi.org/10.2144/btn-2019-0110>
- Chia, S.-L., Yusoff, K., & Shafee, N. (2014). Viral persistence in colorectal cancer cells infected by Newcastle disease virus. *Virology Journal*, 11(1), 91. <https://doi.org/10.1186/1743-422X-11-91>
- Chicote, J., Yuste, V. J., Boix, J., & Ribas, J. (2020). Cell Death Triggered by the Autophagy Inhibitory Drug 3-Methyladenine in Growing Conditions Proceeds With DNA Damage. *Frontiers in Pharmacology*, 11. <https://doi.org/10.3389/fphar.2020.580343>
- Chiu, L.-Y., Hu, M.-E., Yang, T.-Y., Hsin, I.-L., Ko, J.-L., Tsai, K.-J., & Sheu, G.-T. (2015). Immunomodulatory Protein from *Ganoderma microsporum* Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer Cells. *PLOS ONE*, 10(5), e0125774. <https://doi.org/10.1371/journal.pone.0125774>
- Ch'Ng, W. C., Stanbridge, E. J., Yusoff, K., & Shafee, N. (2013). The oncolytic activity of newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: The interplay between von hippel-lindau and interferon- $\beta$  signaling. *Journal of Interferon and Cytokine Research*, 33(7), 346–354. <https://doi.org/10.1089/jir.2012.0095>
- Choi, K. S. (2017). Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines. In *Clinical and Experimental Vaccine Research* (Vol. 6, Issue 2, pp. 72–82). Korean Vaccine Society. <https://doi.org/10.7774/cevr.2017.6.2.72>
- Choi, Y., Bowman, J. W., & Jung, J. U. (2018). Autophagy during viral infection — a double-edged sword. *Nature Reviews Microbiology*, 16(6), 341–354. <https://doi.org/10.1038/s41579-018-0003-6>
- Chude, C. I., & Amaravadi, R. K. (2017). Targeting autophagy in cancer: Update on clinical trials and novel inhibitors. *International Journal of Molecular Sciences*, 18(6). <https://doi.org/10.3390/ijms18061279>
- Cook, K. L., Warri, A., Soto-Pantoja, D. R., Clarke, P. A., Cruz, M. I., Zwart, A., & Clarke, R. (2014). Hydroxychloroquine Inhibits Autophagy to Potentiate

Antiestrogen Responsiveness in ER+ Breast Cancer. *Clinical Cancer Research*, 20(12), 3222–3232. <https://doi.org/10.1158/1078-0432.CCR-13-3227>

Cuoco, J. A., Rogers, C. M., & Mittal, S. (2021). The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma. *Neurosurgical Focus*, 50(2), 1–9. <https://doi.org/10.3171/2020.11.FOCUS20842>

Department of Statistics Malaysia. (2020). *Statistics on Cause of Death, Malaysia, 2020*. Department of Statistics Malaysia. [https://www.dosm.gov.my/v1/index.php?r=column/cthemByCat&cat=401&bul\\_id=QTU5T0dKQ1g4MHYxd3ZpMzhEMzdRdz09&menu\\_id=L0pheU43NWJwRWVVSZkiWdzQ4TIhUUT09](https://www.dosm.gov.my/v1/index.php?r=column/cthemByCat&cat=401&bul_id=QTU5T0dKQ1g4MHYxd3ZpMzhEMzdRdz09&menu_id=L0pheU43NWJwRWVVSZkiWdzQ4TIhUUT09)

Dortmans, J. C. F. M., Koch, G., Rottier, P. J. M., & Peeters, B. P. H. (2011). Virulence of Newcastle disease virus: what is known so far? *Veterinary Research*, 42(122), 1–11.

Elankumaran, S., Chavan, V., Qiao, D., Shobana, R., Moorkanat, G., Biswas, M., & Samal, S. K. (2010). Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy. *Journal of Virology*, 84(8), 3835–3844. <https://doi.org/10.1128/JVI.01553-09>

Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *International Journal of Cancer*, 144(8), 1941–1953. <https://doi.org/10.1002/ijc.31937>

Fiola, C., Peeters, B., Fournier, P., Arnold, A., Bucur, M., & Schirmacher, V. (2006). Tumor selective replication of Newcastle Disease Virus: Association with defects of tumor cells in antiviral defence. *International Journal of Cancer*, 119(2), 328–338. <https://doi.org/10.1002/ijc.21821>

Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., Galun, E., & Siegal, T. (2006). Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. *Molecular Therapy*, 13(1), 221–228. <https://doi.org/10.1016/j.ymthe.2005.08.016>

Gao, P., Bauvy, C., Souquère, S., Tonelli, G., Liu, L., Zhu, Y., Qiao, Z., Bakula, D., Proikas-Cezanne, T., Pierron, G., Codogno, P., Chen, Q., & Mehrpour, M. (2010). The Bcl-2 Homology Domain 3 Mimetic Gossypol Induces Both Beclin 1-dependent and Beclin 1-independent Cytoprotective Autophagy in Cancer Cells. *Journal of Biological Chemistry*, 285(33), 25570–25581. <https://doi.org/10.1074/jbc.M110.118125>

Ghrichi, M., el Zowalaty, M., Omar, A. R., & Ideris, A. (2013). Newcastle disease virus Malaysian strain AF2240 induces apoptosis in MCF-7 human breast carcinoma cells at an early stage of the virus life cycle. *International Journal*

of Molecular Medicine, 31(3), 525–532.  
<https://doi.org/10.3892/ijmm.2013.1244>

- Glick, D., Barth, S., & Macleod, K. F. (2010). Autophagy: cellular and molecular mechanisms. *Journal of Pathology*, 221(1), 3–12.  
<https://doi.org/10.1002/path.2697>.Autophagy
- Han, H. (2018). RNA Interference to Knock Down Gene Expression. In *Methods in Molecular Biology* (Vol. 1706, pp. 293–302). Humana Press Inc.  
[https://doi.org/10.1007/978-1-4939-7471-9\\_16](https://doi.org/10.1007/978-1-4939-7471-9_16)
- Hansen, S. H., Olsson, A., & Casanova, J. E. (1995). Wortmannin, an inhibitor of phosphoinositide 3-kinase, inhibits transcytosis in polarized epithelial cells. *Journal of Biological Chemistry*, 270(47), 28425–28432.  
<https://doi.org/10.1074/jbc.270.47.28425>
- Harper, J., Burke, S., Travers, J., Rath, N., Leinster, A., Navarro, C., Franks, R., Leyland, R., Mulgrew, K., McGlinchey, K., Brown, L., Dovedi, S. J., Koopmann, J. O., Durham, N. M., Cheng, X., Jin, H., Eyles, J., Wilkinson, R. W., & Carroll, D. (2021). Recombinant newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity. *Molecular Cancer Therapeutics*, 20(9), 1723–1734.  
<https://doi.org/10.1158/1535-7163.MCT-20-0902/673403/AM/RECOMBINANT-NEWCASTLE-DISEASE-VIRUS-IMMUNOTHERAPY>
- He, C., & Klionsky, D. (2010). Regulation Mechanisms and Signaling Pathways of Autophagy. *Annual Review of Genetics*, 43, 67–93.  
<https://doi.org/10.1146/annurev-genet-102808-114910>.Regulation
- Hu, L., Sun, S., Wang, T., Li, Y., Jiang, K., Lin, G., Ma, Y., Barr, M. P., Song, F., Zhang, G., & Meng, S. (2015). Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. *American Journal of Cancer Research*, 5(12), 3612–3623. <http://www.ncbi.nlm.nih.gov/pubmed/26885450>
- Jackson, W. T. (2015). Viruses and the autophagy pathway. *Virology*, 479–480, 450–456. <https://doi.org/10.1016/j.virol.2015.03.042>
- Janke, M., Peeters, B., de Leeuw, O., Moorman, R., Arnold, A., Fournier, P., & Schirmacher, V. (2007). Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. *Gene Therapy*, 14(23), 1639–1649.  
<https://doi.org/10.1038/sj.gt.3303026>
- Jiang, K., Li, Y., Zhu, Q., Xu, J., Wang, Y., Deng, W., Liu, Q., Zhang, G., & Meng, S. (2014). Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells. *BMC Cancer*, 14(1), 551. <https://doi.org/10.1186/1471-2407-14-551>

- Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010). mTOR regulation of autophagy. *FEBS Letters*, 584(7), 1287–1295. <https://doi.org/10.1016/j.febslet.2010.01.017>
- Kalantari, A., Farashi Bonab, S., Keyvanfar, H., & Mortazavi, P. (2020). Evaluation of apoptosis induction by newcastle disease virus lasota strain in human breast carcinoma cells. *Archives of Razi Institute*, 75(3), 367–376. <https://doi.org/10.22092/ARI.2019.125824.1322>
- Kalyanasundram, J., Hamid, A., Yusoff, K., & Chia, S. L. (2018). Newcastle disease virus strain AF2240 as an oncolytic virus: A review. *Acta Tropica*, 183(February), 126–133. <https://doi.org/10.1016/j.actatropica.2018.04.007>
- Kelly, E., & Russell, S. J. (2007). History of oncolytic viruses: Genesis to genetic engineering. *Molecular Therapy*, 15(4), 651–659. <https://doi.org/10.1038/sj.mt.6300108>
- Khurana, A., Roy, D., Kalogera, E., Mondal, S., Wen, X., He, X., Dowdy, S., & Shridhar, V. (2015). Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. *Oncotarget*, 6(34), 36354–36369. <https://doi.org/10.18632/oncotarget.5632>
- King, A. M. Q., Adams, M. J., Carstens, E. B., & Lefkowitz, E. J. (Eds.). (2012). Family - Paramyxoviridae. In *Virus Taxonomy: Ninth Report of the International Committee of Viruses* (pp. 672–685). Elsevier. <https://doi.org/10.1016/B978-0-12-384684-6.00056-2>
- Krishnamurthy, S., Takimoto, T., Scroggs, R. A., & Portner, A. (2006). Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell Lines. *Journal of Virology*, 80(11), 5145–5155. <https://doi.org/10.1128/jvi.02618-05>
- Latt, S. A., & Stetten, G. (1976). Spectral studies on 33258 Hoechst and related bisbenzimidazole dyes useful for fluorescent detection of deoxyribonucleic acid synthesis. *Journal of Histochemistry & Cytochemistry*, 24(1), 24–33. <https://doi.org/10.1177/24.1.943439>
- Latt, S. A., Stetten, G., Juergens, L. A., Willard, H. F., & Scher, C. D. (1975). Recent developments in the detection of deoxyribonucleic acid synthesis by 33258 Hoechst fluorescence. *Journal of Histochemistry & Cytochemistry*, 23(7), 493–505. <https://doi.org/10.1177/23.7.1095650>
- Law, B. Y. K., Mok, S. W. F., Chan, W. K., Xu, S. W., Wu, A. G., Yao, X. J., Wang, J. R., Liu, L., & Wong, V. K. W. (2016). Hernandezine, a novel AMPK activator induces autophagic cell death in drug-resistant cancers. *Oncotarget*, 7(7), 8090–8104. <https://doi.org/10.18632/oncotarget.6980>
- Levine, B. (2005). Eating Oneself and Uninvited Guests. *Cell*, 120(2), 159–162. <https://doi.org/10.1016/j.cell.2005.01.005>



- Levine, B., Mizushima, N., & Virgin, H. W. (2011). Autophagy in immunity and inflammation. *Nature*, 469(7330), 323–335. <https://doi.org/10.1038/nature09782>
- Levy, J. M. M., Towers, C. G., & Thorburn, A. (2017). Targeting autophagy in cancer. *Nature Reviews Cancer*, 17(9), 528–542. <https://doi.org/10.1038/nrc.2017.53>
- Li, L. qing, Xie, W. jun, Pan, D., Chen, H., & Zhang, L. (2016). Inhibition of autophagy by bafilomycin A1 promotes chemosensitivity of gastric cancer cells. *Tumor Biology*, 37(1), 653–659. <https://doi.org/10.1007/s13277-015-3842-z>
- Liang, B., Liu, X., Liu, Y., Kong, D., Liu, X., Zhong, R., & Ma, S. (2016). Inhibition of autophagy sensitizes MDR-phenotype ovarian cancer SKVCR cells to chemotherapy. *Biomedicine & Pharmacotherapy*, 82, 98–105. <https://doi.org/10.1016/j.biopha.2016.04.054>
- Lin, J. F., Lin, Y. C., Tsai, T. F., Chen, H. E., Chou, K. Y., & Hwang, T. I. S. (2017). Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells. *Drug Design, Development and Therapy*, 11, 1517–1533. <https://doi.org/10.2147/DDDT.S126464>
- Loo, D. T., & Rillema, J. R. (1998). Chapter 14 Measurement of Cell Death. In *Methods in Cell Biology* (Vol. 57, Issue 57, pp. 251–264). [https://doi.org/10.1016/S0091-679X\(08\)61583-6](https://doi.org/10.1016/S0091-679X(08)61583-6)
- Lu, X., Nikaido, T., Toki, T., Zhai, Y. L., Kita, N., Konishi, I., & Fujii, S. (2000). Loss of heterozygosity among tumor suppressor genes in invasive and in situ carcinoma of the uterine cervix. *International Journal of Gynecological Cancer*, 10(6), 452–458. <https://doi.org/10.1046/j.1525-1438.2000.00071.x>
- Lun, X. Q., Alain, T., Zemp, F. J., Zhou, H., Rahman, M. M., Hamilton, M. G., McFadden, G., Bell, J., Senger, D. L., & Forsyth, P. A. (2010). Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. *Cancer Research*, 70(2), 598–608. <https://doi.org/10.1158/0008-5472.CAN-09-1510>
- Lun, X. Q., Jang, J. H., Tang, N., Deng, H., Head, R., Bell, J. C., Stojdl, D. F., Nutt, C. L., Senger, D. L., Forsyth, P. A., & McCart, J. A. (2009). Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 15(8), 2777–2788. <https://doi.org/10.1158/1078-0432.CCR-08-2342>
- MacDonald, M. L., Lamerdin, J., Owens, S., Keon, B. H., Bilter, G. K., Shang, Z., Huang, Z., Yu, H., Dias, J., Minami, T., Michnick, S. W., & Westwick, J. K. (2006). Identifying off-target effects and hidden phenotypes of drugs in

- human cells. *Nature Chemical Biology*, 2(6), 329–337. <https://doi.org/10.1038/nchembio790>
- Manic, G., Obrist, F., Kroemer, G., Vitale, I., & Galluzzi, L. (2014). Chloroquine and hydroxychloroquine for cancer therapy. *Molecular and Cellular Oncology*, 1(1), 1–11. <https://doi.org/10.4161/mco.29911>
- Mansour, M., Palese, P., & Zamarin, D. (2011). Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells. *Journal of Virology*, 85(12), 6015–6023. <https://doi.org/10.1128/JVI.01537-10>
- Maroun, J., Muñoz-Alía, M., Ammayappan, A., Schulze, A., Peng, K. W., & Russell, S. (2017). Designing and building oncolytic viruses. *Future Virology*, 12(4), 193–213. <https://doi.org/10.2217/fvl-2016-0129>
- Martin, K. J., Graner, E., Li, Y., Price, L. M., Kritzman, B. M., Fournier, M. v., Rhei, E., & Pardee, A. B. (2001). High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. *Proceedings of the National Academy of Sciences of the United States of America*, 98(5), 2646–2651. <https://doi.org/10.1073/pnas.041622398>
- Meng, C., Zhou, Z., Jiang, K., Yu, S., Jia, L., Wu, Y., Liu, Y., Meng, S., & Ding, C. (2012). Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. *Archives of Virology*, 157(6), 1011–1018. <https://doi.org/10.1007/s00705-012-1270-6>
- Meng, G., Xia, M., Wang, D., Chen, A., Wang, Y., Yu, D., & Wei, J. (2014). Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells. *Oncotarget*, 5(15).
- Mohamed Amin, Z., Che Ani, M. A., Tan, S. W., Yeap, S. K., Alitheen, N. B., Syed Najmuddin, S. U. F., Kalyanasundram, J., Chan, S. C., Veerakumarasivam, A., Chia, S. L., & Yusoff, K. (2019). Evaluation of a Recombinant Newcastle Disease Virus Expressing Human IL12 against Human Breast Cancer. *Scientific Reports*, 9(1). <https://doi.org/10.1038/s41598-019-50222-z>
- Morris, C. T. and D. G. (2009). Oncolytic Viral Therapy Using Reovirus Chandini Thirukkumaran and Don G. Morris. In *Methods in Molecular Biology, Gene, Gene Therapy of Cancer* (Vol. 542, Issue 1). <https://doi.org/10.1007/978-1-59745-561-9>
- Murulitharan, K., Yusoff, K., Omar, A. R., & Molouki, A. (2013). Characterization of Malaysian velogenic NDV strain AF2240-I genomic sequence: A comparative study. *Virus Genes*, 46(3), 431–440. <https://doi.org/10.1007/s11262-012-0874-y>
- Najmuddin, S. U. F. S., Amin, Z. M., Tan, S. W., Yeap, S. K., Kalyanasundram, J., Ani, M. A. C., Veerakumarasivam, A., Chan, S. C., Chia, S. L., Yusoff,

- K., & Alitheen, N. B. (2020). Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo. *Cancer Cell International*, 20(1), 278. <https://doi.org/10.1186/S12935-020-01372-Y>
- National Cancer Institute. (2018, December 28). Cancer-Causing Substances in the Environment. <https://www.cancer.gov/about-cancer/causes-prevention/risk/substances>
- National Cancer Institute. (2021). What Is Cancer? - National Cancer Institute. National Cancer Institute. <http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer>
- National Health Service. (2019). Breast cancer in women - Causes - NHS. National Health Service. <https://www.nhs.uk/conditions/breast-cancer/causes/>
- Othman, F., Ideris, A., Motalleb, G., Eshak, Z. Bt., & Rahmat, A. (2010). Oncolytic Effect of Newcastle Disease Virus AF2240 Strain on the MCF-7 Breast Cancer Cell Line. *Cell Journal (Yakhteh)*, 12(1), 17. <https://www.magiran.com/paper/728534>
- Park, M.-S., Garcia-Sastre, A., Cros, J. F., Basler, C. F., & Palese, P. (2003). Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction. *Journal of Virology*, 77(17), 9522–9532. <https://doi.org/10.1128/jvi.77.17.9522-9532.2003>
- Pasquier, B. (2015). SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells. *Autophagy*, 11(4), 725–726. <https://doi.org/http://dx.doi.org/10.1080/15548627.2015.1033601>
- Pasquier, B. (2016). Autophagy inhibitors. *Cellular and Molecular Life Sciences*, 73(5), 985–1001. <https://doi.org/10.1007/s00018-015-2104-y>
- Prince, A. M., & Ginsberg, H. S. (1957). Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. I. Characteristics of the virus-cell interaction. *Journal of Immunology (Baltimore, Md. : 1950)*, 79(2), 94–106. <http://www.ncbi.nlm.nih.gov/pubmed/13475814>
- Ramamurthy, N., Pathak, D. C., D'Silva, A. L., Batheja, R., Mariappan, A. K., Vakharia, V. N., Chellappa, M. M., & Dey, S. (2021). Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro. *Research in Veterinary Science*, 139, 159–165. <https://doi.org/10.1016/J.RVSC.2021.07.028>
- Redmann, M., Benavides, G. A., Berryhill, T. F., Wani, W. Y., Ouyang, X., Johnson, M. S., Ravi, S., Barnes, S., Darley-USmar, V. M., & Zhang, J. (2017). Inhibition of autophagy with bafilomycin and chloroquine decreases mitochondrial quality and bioenergetic function in primary neurons. *Redox*

- Rohatgi, R. A., Janusis, J., Leonard, D., Bellvé, K. D., Fogarty, K. E., Baehrecke, E. H., Corvera, S., & Shaw, L. M. (2015). Beclin 1 regulates growth factor receptor signaling in breast cancer. *Oncogene*, 34(42), 5352–5362. <https://doi.org/10.1038/onc.2014.454>
- Ronan, B., Flamand, O., Vescovi, L., Dureuil, C., Durand, L., Fassy, F., Bachelot, M., Lambertson, A., Mathieu, M., Bertrand, T., Marquette, J., El-ahmad, Y., Filoche-romme, B., Schio, L., Garcia-echeverria, C., Goulaouic, H., & Pasquier, B. (2014). A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. *Nature Chemical Biology*, 1–7. <https://doi.org/10.1038/nchembio.1681>
- Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., Abdollahpour, I., Abdulkader, R. S., Abebe, H. T., Abebe, M., Abebe, Z., Abejie, A. N., Abera, S. F., Abil, O. Z., Abraha, H. N., ... Murray, C. J. L. (2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*, 392(10159), 1736–1788. [https://doi.org/10.1016/S0140-6736\(18\)32203-7](https://doi.org/10.1016/S0140-6736(18)32203-7)
- Russell, S. J., Peng, K.-W., & Bell, J. C. (2012). Oncolytic virotherapy. *Nature Biotechnology*, 30(7), 658–670. <https://doi.org/10.1038/nbt.2287>
- Schlütermann, D., Skowron, M. A., Berleth, N., Böhler, P., Deitersen, J., Stuhldreier, F., Wallot-Hieke, N., Wu, W., Peter, C., Hoffmann, M. J., Niegisch, G., & Stork, B. (2018). Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. *Urologic Oncology: Seminars and Original Investigations*, 36(4), 160.e1-160.e13. <https://doi.org/10.1016/j.urolonc.2017.11.021>
- Shao, X., Wang, X., Guo, X., Jiang, K., Ye, T., Chen, J., Fang, J., Gu, L., Wang, S., Zhang, G., Meng, S., & Xu, Q. (2019). STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells. *Frontiers in Oncology*, 9(MAY). <https://doi.org/10.3389/fonc.2019.00436>
- Shi, C., Zhang, Z., Shi, J., Wang, F., & Luan, Y. (2015). Co-delivery of docetaxel and chloroquine via PEO–PPO–PCL/TPGS micelles for overcoming multidrug resistance. *International Journal of Pharmaceutics*, 495(2), 932–939. <https://doi.org/10.1016/j.ijpharm.2015.10.009>
- Sinkovics, J. G., & Horvath, J. C. (2000). Newcastle disease virus (NDV): Brief history of its oncolytic strains. *Journal of Clinical Virology*, 16(1), 1–15. [https://doi.org/10.1016/S1386-6532\(99\)00072-4](https://doi.org/10.1016/S1386-6532(99)00072-4)

- Slater, T. F., Sawyer, B., & Sträuli, U. (1963). Studies on succinate-tetrazolium reductase systems. *Biochimica et Biophysica Acta*, 77(C), 383–393. [https://doi.org/10.1016/0006-3002\(63\)90513-4](https://doi.org/10.1016/0006-3002(63)90513-4)
- Song, H., Zhong, L.-P., He, J., Huang, Y., & Zhao, Y.-X. (2019). Application of Newcastle disease virus in the treatment of colorectal cancer. *World Journal of Clinical Cases*, 7(16), 2143–2154. <https://doi.org/10.12998/wjcc.v7.i16.2143>
- Toth, C. A., & Thomas, P. (1992). Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo. *British Journal of Cancer*, 65(3), 365–368. <https://doi.org/10.1038/bjc.1992.74>
- Tsukada, M., & Ohsumi, Y. (1993). Isolation and characterization of autophagy-defective mutants of *Saccharomyces cerevisiae*. *Federation of European Biochemical Societies*, 333(1), 169–174.
- Vijayakumar, G., McCroskery, S., & Palese, P. (2020). Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. *Journal of Virology*, 94(3). <https://doi.org/10.1128/JVI.01677-19>
- Viret, C., Rozières, A., & Faure, M. (2018). Autophagy during Early Virus–Host Cell Interactions. *Journal of Molecular Biology*, 430(12), 1696–1713. <https://doi.org/10.1016/j.jmb.2018.04.018>
- Voit, C., Kron, M., Schwürzer-Voit, M., & Sterry, W. (2003). Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease. *JDDG - Journal of the German Society of Dermatology*, 1(2), 120–125. <https://doi.org/10.1046/j.1610-0387.2003.02014.x>
- Wang, C., Hu, Q., & Shen, H. M. (2016). Pharmacological inhibitors of autophagy as novel cancer therapeutic agents. *Pharmacological Research*, 105, 164–175. <https://doi.org/10.1016/j.phrs.2016.01.028>
- Wang, C., Wang, X., Su, Z., Fei, H., Liu, X., & Pan, Q. (2015). The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth. *Oncology Reports*, 34(4), 1708–1716. <https://doi.org/10.3892/or.2015.4146>
- Wang, C., Wang, Y., McNutt, M. A., & Zhu, W. G. (2011). Autophagy process is associated with anti-neoplastic function. *Acta Biochimica et Biophysica Sinica*, 43(6), 425–432. <https://doi.org/10.1093/abbs/gmr028>
- Wang, J. (2008). Beclin 1 bridges autophagy, apoptosis and differentiation. *Autophagy*, 4(7), 947–948. <https://doi.org/10.4161/auto.6787>

- Wang, Y., Jiang, K., Zhang, Q., Meng, S., & Ding, C. (2018). Autophagy in Negative-Strand RNA Virus Infection. *Frontiers in Microbiology*, 9. <https://doi.org/10.3389/fmicb.2018.00206>
- Wang, Y., Peng, R. Q., Li, D. D., Ding, Y., Wu, X. Q., Zeng, Y. X., Zhu, X. F., & Zhang, X. S. (2011). Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells. *Chinese Journal of Cancer*, 30(10), 690–700. <https://doi.org/10.5732/cjc.011.10056>
- Warhurst, D. C., Steele, J. C. P., Adagu, I. S., Craig, J. C., & Cullander, C. (2003). Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant *Plasmodium falciparum*, in agreement with its physicochemical properties. *Journal of Antimicrobial Chemotherapy*, 52(2), 188–193. <https://doi.org/10.1093/jac/dkg319>
- Watkins, A. M., Chan, P. J., Kalugdan, T. H., Patton, W. C., Jacobson, J. D., & King, A. (1996). Analysis of the flow cytometer stain Hoechst 33342 on human spermatozoa. *Molecular Human Reproduction*, 2(9), 709–712. <https://doi.org/10.1093/molehr/2.9.709>
- World Health Organization. (2021). Cancer. World Health Organization. <https://www.who.int/en/news-room/fact-sheets/detail/cancer>
- Wu, Y. C., Wu, W. K. K., Li, Y., Yu, L., Li, Z. J., Wong, C. C. M., Li, H. T., Sung, J. J. Y., & Cho, C. H. (2009). Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. *Biochemical and Biophysical Research Communications*, 382(2), 451–456. <https://doi.org/10.1016/j.bbrc.2009.03.051>
- Wu, Y., He, J., An, Y., Wang, X., Liu, Y., Yan, S., Ye, X., Qi, J., Zhu, S., Yu, Q., Yin, J., Li, D., & Wang, W. (2016). Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. *Journal of Pharmacological Sciences*, 132(1), 24–30. <https://doi.org/10.1016/j.jphs.2016.03.012>
- Wu, Y., Zhang, X., Wang, X., Wang, L., Hu, S., Liu, X., & Meng, S. (2012). Apoptin enhances the oncolytic properties of Newcastle disease virus. *Intervirology*, 55(4), 276–286. <https://doi.org/10.1159/000328325>
- Wu, Y.-T., Tan, H.-L., Shui, G., Bauvy, C., Huang, Q., Wenk, M. R., Ong, C.-N., Codogno, P., & Shen, H.-M. (2010). Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-Kinase. *Journal of Biological Chemistry*, 285(14), 10850–10861. <https://doi.org/10.1074/jbc.M109.080796>
- Xiao, Y., & Cai, W. (2020). Autophagy and Viral Infection. In *Advances in Experimental Medicine and Biology* (Vol. 1207, pp. 425–432). Springer Singapore. [https://doi.org/10.1007/978-981-15-4272-5\\_30](https://doi.org/10.1007/978-981-15-4272-5_30)
- Yamamoto, A., Tagawa, Y., Yoshimori, T., Moriyama, Y., Masaki, R., & Tashiro, Y. (1998). Bafilomycin Ai Prevents Maturation of Autophagic Vacuoles by

Inhibiting Fusion between Autophagosomes and Lysosomes in Rat Hepatoma Cell Line. *Cell Structure and Function*, 23, 33–42.

Yang, H. Z., Ma, Y., Zhou, Y., Xu, L. M., Chen, X. J., Ding, W. bin, & Zou, H. B. (2015). Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment. *Cancer Letters*, 361(1), 128–136. <https://doi.org/10.1016/j.canlet.2015.02.045>

Yayon, A., Cabantchik, Z. I., & Ginsburg, H. (1984). Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. *The EMBO Journal*, 3(11), 2695–2700. <https://doi.org/10.1002/j.1460-2075.1984.tb02195.x>

Ye, H., Chen, M., Cao, F., Huang, H., Zhan, R., & Zheng, X. (2016). Chloroquine, an autophagy inhibitor, potentiates the radiosensitivity of glioma initiating cells by inhibiting autophagy and activating apoptosis. *BMC Neurology*, 16(1), 1–8. <https://doi.org/10.1186/s12883-016-0700-6>

Yonekawa, T., & Thorburn, A. (2013). Autophagy and cell death. *Essays In Biochemistry*, 55, 105–117. <https://doi.org/10.1042/bse0550105>

Yoon, Y. H., Cho, K. S., Hwang, J. J., Lee, S. J., Choi, J. A., & Koh, J. Y. (2010). Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. *Investigative Ophthalmology and Visual Science*, 51(11), 6030–6037. <https://doi.org/10.1167/iovs.10-5278>

Yoshii, S. R., & Mizushima, N. (2017). Monitoring and Measuring Autophagy. *International Journal of Molecular Sciences*, 18(9), 1865. <https://doi.org/10.3390/ijms18091865>

Yu, X., Luo, A., Liu, Y., Wang, S., Li, Y., Shi, W., Liu, Z., & Qu, X. (2015). MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. *Molecular Cancer*, 14(1), 1–16. <https://doi.org/10.1186/s12943-015-0480-4>

Yusoff, K., & Wen Siang Tan. (2001). Newcastle disease virus: Macromolecules and opportunities. In *Avian Pathology* (Vol. 30, Issue 5, pp. 439–455). <https://doi.org/10.1080/03079450120078626>

Zamarin, D., & Palese, P. (2012). Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. *Future Microbiology*, 7(3), 347–367. <https://doi.org/10.2217/fmb.12.4>

Zhang, L., Yang, A., Wang, M., Liu, W., Wang, C., Xie, X., Chen, X., Dong, J., & Li, M. (2016). Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. *Apoptosis*, 21(4), 473–488. <https://doi.org/10.1007/s10495-016-1214-9>

Zink, D., Fischer, A. H., & Nickerson, J. A. (2004). Nuclear structure in cancer cells. *Nature Reviews Cancer*, 4(9), 677–687. <https://doi.org/10.1038/nrc1430>